As you prepare to begin your next phase of therapy, we want to ensure your treatment aligns with your body composition, clinical needs, and lifestyle preferences. Because The Charleston Atelier currently stocks both the synergistic CJC-1295/Ipamorelin pen and the single-agent Tesamorelin pen, Dr. Kendall has outlined a side-by-side comparison to help you select the clinical pathway that feels right for you.
Understanding the two options
1. CJC-1295 + Ipamorelin (The Foundation Protocol)
This protocol combines a growth hormone-releasing hormone (CJC-1295) with a growth hormone secretagogue (Ipamorelin) in a single, synergistic blend.
- The clinical mechanism: CJC-1295 delivers a gentle, continuous signal to your pituitary gland to produce growth hormone, while Ipamorelin mimics and shapes your body's natural, youthful nightly hormone pulses.
- Primary clinical target: Broad systemic rejuvenation, deep sleep architecture, physical tissue recovery, and skin and joint elasticity.
- Pituitary stress and tolerability: Excellent. It is exceptionally gentle on pituitary receptors and carries a very low risk of receptor desensitization or initial water retention.
2. Standalone Tesamorelin (The Visceral Fat Specialist)
This protocol uses a highly potent, FDA-approved growth hormone-releasing hormone (GHRH) on its own.
- The clinical mechanism: Tesamorelin is highly selective and potently stimulates the synthesis and release of endogenous growth hormone.
- Primary clinical target: Aggressive, targeted reduction of resistant visceral adipose tissue: the deep abdominal fat surrounding the internal organs that is typically resistant to traditional diet, exercise, or GLP-1 therapy.
- Pituitary stress and tolerability: Highly potent. Because it is a much stronger pituitary stimulant, it requires careful cycling and carries a slightly higher initial chance of transient fluid retention or joint stiffness as your body adapts.
Optional add-on to your stack: Wolverine Blend (tissue repair and recovery)
As a non-growth-hormone-stimulating option, the Wolverine Blend (BPC-157 and TB-500) works independently of the pituitary pathway to focus entirely on targeted cellular repair, injury recovery, and anti-inflammatory support. It can be used as a standalone protocol or safely stacked alongside growth hormone secretagogues for comprehensive physical rehabilitation.
Combining Wolverine Blend with growth hormone secretagogues
While growth hormone secretagogues (CJC-1295/Ipamorelin or Tesamorelin) focus on systemic optimization, deep sleep architecture, and metabolic support, the Wolverine Blend specifically targets cellular repair and tissue recovery. Because they operate through entirely independent pathways, they can be used together safely and effectively.
- Synergistic mechanism: Secretagogues optimize your body's natural growth hormone pulses to support overall cellular turnover, while BPC-157 and TB-500 direct targeted healing to joints, tendons, ligaments, and areas of physical stress or injury.
- Administration strategy: Because their mechanisms do not overlap, they can run concurrently without receptor competition. Secretagogues are typically administered as a nightly fasted injection (5 days on, 2 days off), whereas the Wolverine Blend is generally administered subcutaneously 2 to 3 times per week.
Protocol comparison matrix
| Peptide protocol | CJC-1295 + Ipamorelin (Foundation) | Standalone Tesamorelin (Premium GHRH) | Wolverine Blend (BPC-157 / TB-500) |
|---|---|---|---|
| Primary focus | Overall cellular repair, recovery, deep sleep, and skin tone. | Targeted, aggressive deep abdominal (visceral) fat loss. | Accelerated tissue repair, injury recovery, and anti-inflammatory support. |
| Tolerability profile | Extremely high; very gentle on systemic pathways. | Powerful and fast-acting; requires strategic, monitored cycles. | Excellent; targeted healing without hormonal receptor stimulation. |
| Typical 30-day response | Deeper sleep by night 4; improved waking freshness and muscle recovery by week 4. | Softening of deep midsection fat and visible waistline changes by week 4. | Noticeable reduction in joint discomfort, improved mobility, and enhanced recovery from physical exertion by week 4. |
| Administration cadence | One subcutaneous injection nightly, fasted (5 days on, 2 days off). | One subcutaneous injection nightly, fasted (5 days on, 2 days off). | Subcutaneous injection 2 to 3 times per week. |
Monthly transition timeline
Whichever protocol you select, your body will transition through these predictable phases during your first 30 days:
- Week 1 (days 1 to 7), circadian realignment: Your body adapts to the peptide signaling. Deeper, more restorative sleep patterns typically establish within 3 to 4 nights.
- Week 2 (days 8 to 14), systemic adaptation: The weekly "5 days active, 2 days off" schedule (for example, injecting Sunday evening through Thursday evening and resting Friday and Saturday) becomes routine.
- Week 3 (days 15 to 21), cellular reorganization: The peptides work continuously behind the scenes. Internal fat mobilization and tissue repair processes peak during this quiet, foundational phase.
- Week 4 (days 22 to 30), structural shifts: You will experience more stable morning energy, natural fluid balance, and initial measurable changes in body composition on the tape measure.
Choosing your protocol in Charleston
Both pens are prescribed and supervised in person by Kendall Phelps-Polirer, MD at 83 Cannon Street, and both are available at member pricing alongside the All-Inclusive GLP-1 Face & Body Protocol Membership. If you are unsure which pathway fits, the two-minute protocol quiz is the simplest place to start, followed by a private consultation. Read more about peptide therapy at The Charleston Atelier or the patient guide to peptide therapy.
General education, not individual medical advice. Peptide protocols are prescription therapies determined by a physician after evaluation. Compounded peptides are prepared by a licensed pharmacy and are not FDA-approved for these uses; Tesamorelin's FDA approval is for a specific indication. Timelines describe typical experiences; individual results vary.